Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in California: - Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- City of Hope Corona — Corona, California
- UC Irvine Health Cancer Center-Newport — Costa Mesa, California
- Kaiser Permanente Downey Medical Center — Downey, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente-Fontana — Fontana, California
- Kaiser Permanente South Bay — Harbor City, California
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in California: - Research Site — Clovis, California
- Research Site — Los Alamitos, California
- Research Site — San Diego, California
- Research Site — Santa Monica, California
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in California: - Alta Bates Summit Medical Center ( Site 0004) — Berkeley, California
- Moores Cancer Center ( Site 0003) — La Jolla, California
- Care Access - South Pasadena ( Site 0070) — Pasadena, California
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in California: - City of Hope Cancer Center — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- University of California Los Angeles — Los Angeles, California
- St. Joseph Hospital Center for Cancer Prevention and Treatment — Orange, California
- Stanford University Medical Center — Stanford, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- City of Hope Cancer Center — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica — Santa Monica, California
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in California: - David Geffen School of Medicine at UCLA — Los Angeles, California
- UC Irvine Health — Orange, California
Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Sites in California: - MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
Phase 3 Recruiting Industry
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primar…
Sponsor: Kite, A Gilead Company
NCT ID: NCT07479797
Sites in California: - City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- Stanford University — Stanford, California
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- PCR Oncology — Arroyo Grande, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Downey Medical Center — Downey, California
- City of Hope Comprehensive Cancer Center — Duarte, California
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Valley Children's Hospital — Madera, California
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope Seacliff — Huntington Beach, California
- City of Hope Antelope Valley — Lancaster, California
- City of Hope at Long Beach Elm — Long Beach, California
Phase 2 Recruiting Academic/Other
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
Phase 2 Recruiting Industry
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…
Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- City of Hope — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
Phase 2 Recruiting Industry
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…
Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in California: - UC San Diego Health — La Jolla, California
- Stanford University — Stanford, California
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in California: - City of Hope — Duarte, California
- Providence St. John's Health Center — Santa Monica, California
- UCLA Department of Medicine - Hematology/Oncology — Santa Monica, California
Phase 2 Recruiting Industry
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in California: - City of Hope — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Scripps Health — San Diego, California
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in California: - City of Hope — Duarte, California
- Children's Hospital Los Angeles — Los Angeles, California
- UCLA Mattel Children's Hospital — Los Angeles, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- UCSF — San Francisco, California
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in California: - Research Site — Duarte, California
Phase 1, Phase 2 Recruiting Industry
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- posi…
Sponsor: Nuvalent Inc.
NCT ID: NCT05384626
Sites in California: - University of California Irvine Medical Center — Orange, California
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/r…
Sponsor: Sellas Life Sciences Group
NCT ID: NCT04588922
Sites in California: - City of Hope National Medical Center — Duarte, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignan…
Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in California: - University of Southern California Norris Comprehensive — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in California: - Children's Hospital Los Angeles ( Site 1006) — Los Angeles, California
Phase 2 Recruiting Industry
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for st…
Sponsor: AstraZeneca
NCT ID: NCT05952024
Sites in California: - Research Site — Berkeley, California
- Research Site — La Jolla, California
- Research Site — Orange, California